Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,487
  • Shares Outstanding, K 30,174
  • Annual Sales, $ 0 K
  • Annual Income, $ -98,790 K
  • EBIT $ -92 M
  • EBITDA $ -92 M
  • 60-Month Beta 0.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.74

Options Overview Details

View History
  • Implied Volatility 287.37% ( +35.03%)
  • Historical Volatility 34.35%
  • IV Percentile 99%
  • IV Rank 90.72%
  • IV High 315.66% on 11/20/24
  • IV Low 10.76% on 08/16/24
  • Put/Call Vol Ratio 2.66
  • Today's Volume 139
  • Volume Avg (30-Day) 697
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 19,498
  • Open Int (30-Day) 15,409

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.55
  • Number of Estimates 2
  • High Estimate -0.52
  • Low Estimate -0.57
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +34.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.73 +2.38%
on 11/21/24
3.98 -29.65%
on 10/28/24
-0.84 (-23.08%)
since 10/22/24
3-Month
2.32 +20.69%
on 09/06/24
3.98 -29.65%
on 10/28/24
unch (unch)
since 08/22/24
52-Week
1.88 +48.94%
on 08/12/24
7.22 -61.23%
on 03/04/24
-0.05 (-1.75%)
since 11/22/23

Most Recent Stories

More News
Relmada Therapeutics Initiates Phase 1 Study of REL-P11, a Low-Dose Psilocybin Formulation for Metabolic Disease

Relmada initiates Phase 1 study for REL-P11, a psilocybin formulation for metabolic disorders, with Phase 2a planned for 2025.Quiver AI SummaryRelmada Therapeutics has announced the initiation of dosing...

RLMD : 2.80 (+1.82%)
2 Breakout Biotech Stocks With CEO Insider Buying

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

DYN : 29.69 (-0.13%)
RLMD : 2.80 (+1.82%)
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.80 (+1.82%)
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.80 (+1.82%)
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.80 (+1.82%)
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.80 (+1.82%)
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.80 (+1.82%)
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.80 (+1.82%)
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.80 (+1.82%)
RLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of...

RLMD : 2.80 (+1.82%)

Business Summary

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an...

See More

Key Turning Points

3rd Resistance Point 3.15
2nd Resistance Point 3.06
1st Resistance Point 2.93
Last Price 2.80
1st Support Level 2.71
2nd Support Level 2.62
3rd Support Level 2.49

See More

52-Week High 7.22
Fibonacci 61.8% 5.18
Fibonacci 50% 4.55
Fibonacci 38.2% 3.92
Last Price 2.80
52-Week Low 1.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar